WEDNESDAY, March 30, 2016 (HealthDay News) -- Defitelio (defibrotide sodium) has been approved by the U.S. Food and Drug Administration to treat a rare, but usually fatal liver disease that affects some people who have had a stem cell transplant.
Latest Digestion News
The condition, fatal in as many as 80 percent of cases, is called hepatic veno-occulusive disease (VOD). It affects people who have had a stem cell transplant to treat cancers of the blood or bone marrow.
Defitelio was investigated in 528 people with hepatic VOD who participated in three clinical studies. The most common side effects included low blood pressure, diarrhea, vomiting, nausea and nosebleed.
Defitelio is marketed by Jazz Pharmaceuticals, based in Palo Alto, Calif.
-- Scott Roberts
Copyright © 2016 HealthDay. All rights reserved.